Drug Profile
MK 3614
Alternative Names: MK-3614Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension in Belgium (PO)
- 27 Jan 2010 Merck completes a phase I study in Hypertension